The successes and failures of HIV drug discovery

Expert Opinion on Drug Discovery

Volumn 6, Issue 10, 2011, Pages 1067-1090

  Hashimoto, Chie ^a   Tanaka, Tomohiro ^a   Narumi, Tetsuo ^a   Nomura, Wataru ^a   Tamamura, Hirokazu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

AIDS; CCR5; CD4 mimic; Chemokine receptor; CXCR4; Fusion; HIV; Integrase

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; ANTIINFECTIVE AGENT; APLAVIROC; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DOLUTEGRAVIR; ELVITEGRAVIR; ENFUVIRTIDE; GLOBOIDNAM; GS 9160; GSK 364735; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE INHIBITOR; L 708906; L 870812; MARAVIROC; MK 0536; MK 2048; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLERIXAFOR; RALTEGRAVIR; T 140; T 649; TIFUVIRTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; DRUG BINDING; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TROPISM; VIRUS INHIBITION; VIRUS STRAIN;

EID: 80053262154     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.611129     Document Type: Review

References (110)

1. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71 (Pubitemid 13080157)
2. Mitsuya H, Erickson J. Drug development. A. Discovery and development of antiretroviral therapeutics for HIV infection. In: Merigan TC, Bartlett JG, Bolognesi D. editors. Textbook of AIDS Medicine. Williams & Wilkins; Baltimore; 1999. p. 751-80
3. Alkhatib G, Combadiere C, Broder CC, et al. CC CKRS: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8 (Pubitemid 26234510)
4. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;6:1135-48 (Pubitemid 26231178)
5. Deng HK, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6 (Pubitemid 26197679)
6. Doranz BJ, Rucker J, Yi YJ, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-58 (Pubitemid 26235280)
7. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73 (Pubitemid 26197680)
8. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7 (Pubitemid 26154590)
9. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998;93:681-4 (Pubitemid 28257575)
10. Wild CT, Greenwell TK, Matthews TJ, et al. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9:1051-3. The discovery of a fusion inhibitor Enfuvirtide.
11. Walker DK, Abel S, Comby P, et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005;33:587-95. The discovery of an entry inhibitor Maraviroc (CCR5 antagonist). (Pubitemid 40393203)
12. Cahn P, Sued O. Raltegravir: A new antiretroviral class for salvage therapy. Lancet 2007;369:1235-6. The discovery of an integrase inhibitor Raltegravir.
13. Grinsztejn B, Nguyen B-Y, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor Raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007;369:1261-9. The discovery of an integrase inhibitor Raltegravir.
14. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2:1075-82
15. Shimura K, Nameki D, Kajiwara K, et al. Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors. J Biol Chem 2010;285:39471-80
16. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-73 (Pubitemid 27199898)
17. Otaka A, Nakamura M, Nameki D, et al. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed 2022;41:2937-40
18. Nishikawa H, Nakamura S, Kodama E, et al. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to Enfuvirtide. Int J Biochem Cell Biol 2009;41:891-9
19. Liu S, Lu H, Xu Y, et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005;280:11259-73. (Pubitemid 40418432)
20. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001;75:8605-14 (Pubitemid 32768965)
21. Veiga AS, Santos NC, Loura LM, et al. HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency. J Am Chem Soc 2004;126:14758-63. The discovery of a fusion inhibitor T-1249, a follow-on to Enfuvirtide. (Pubitemid 39532156)
22. Pierson TC, Doms RW, Pohlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004;14:255-70 (Pubitemid 38879817)
23. Liu S, Jiang S. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: Theories and techniques. Curr Pharm Des 2004;10:1827-43 (Pubitemid 38647464)
24. Si Z, Madani N, Cox JM, et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci USA 2004;101:5036-41 (Pubitemid 38469198)
25. Ferrer M, Kapoor TM, Strassmaier T, et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 1999;6:953-60 (Pubitemid 29463310)
26. Nakahara T, Nomura W, Ohba K, et al. Remodeling of dynamic structures of HIV-1 envelope proteins leads to synthetic antigen molecules inducing neutralizing antibodies. Bioconjug Chem 2010;21:709-14. The development of an HIV vaccine based on trimer mimic of the gp41 HR1 region.
27. Zwick MB, Saphire EO, Burton DR. gp41: HIV's shy protein. Nat Med 2004;10:133-4 (Pubitemid 38524880)
28. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;14:657-700 (Pubitemid 29241137)
29. Abel S, Russell D, Whitlock LA, et al. Assessment of the absorption, metabolism and absolute bioavailability of Maraviroc in healthy male subjects. Br J Clin Pharmacol 2008;65:60-7 (Pubitemid 351366540)
30. Chan PLS, Weatherley B, McFadyen L, et al. A population pharmacokinetic meta-analysis of Maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Br J Clin Pharmacol 2008;65:76-85 (Pubitemid 351366542)
31. Stupple PA, Batchelor DV, Corless M, et al. An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: The discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6, 7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl} acetamide (PF-232798). J Med Chem 2011;54:67-77
32. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-703 (Pubitemid 29234681)
33. Shiraishi M, Aramaki Y, Seto M, et al. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem 2000;43:2049-63 (Pubitemid 30340944)
34. Imamura S, Ishihara Y, Hattori T, et al. CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives. Chem Pharm Bull 2004;52:63-73 (Pubitemid 41685553)
35. Imamura S, Ichikawa T, Nishikawa Y, et al. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent anti-HIV-1 activity. J Med Chem 2006;49:2784-93
36. Tagat JR, McCombie SW, Nazareno DV, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5- pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1 (R)-4-(trifluoromethyl)-phenyl}ethyl- 3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonists. J Med Chem 2003;47:2405-8 (Pubitemid 38580075)
37. Landovitz RJ, Angel JB, Hoffmann C, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008;198:1113-22
38. Gathe J, Diaz R, Fatkenheuer G, et al. Phase 3 trials of Vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens. 17th CROI Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco CA
39. Habashita H, Kokubo M, Hamano S, et al. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists. J Med Chem 2006;49:4140-52 (Pubitemid 44036659)
40. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6 (Pubitemid 32225831)
41. Tamamura H, Hori A, Kanzaki N, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003;550:79-83 (Pubitemid 37281361)
42. Takenaga M, Tamamura H, Hiramatsu K, et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun 2004;320:226-32 (Pubitemid 38781805)
43. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in thecontext of chronic lymphocytic leukemia. Blood 2002;99:1030-7 (Pubitemid 34525568)
44. Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003;17:1294-300 (Pubitemid 36857336)
45. Nanki T, Hayashida K, EI-Gabalawy HS, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4(+) T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000;165:6590-8
46. Tamamura H, Fujisawa M, Hiramatsu K, et al. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett 2004;569:99-104 (Pubitemid 38844600)
47. Tamamura H, Xu Y, Hattori T, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998;253:877-82. The development of a peptidic CXCR4 antagonist T140. (Pubitemid 29039238)
48. Tamamura H, Hiramatsu K, Kusano S, et al. Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives. Org Biomol Chem 2003;1:3656-62
49. Tamamura H, Hiramatsu K, Mizumoto M, et al. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. Org Biomol Chem 2003;1:3663-9. The development of biostable derivatives of a CXCR4 antagonist T140.
50. Fujii N, Oishi S, Hiramatsu K, et al. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation-and sequence-based libraries. Angew Chem Int Ed 2003;42:3251-3 (Pubitemid 36917168)
51. Schols D, Struyf S, Van Damme J, et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-8. The development of a non-peptidic CXCR4 antagonist AMD3100.
52. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003;2:581-7 (Pubitemid 37361749)
53. Pettersson S, Perez-Nueno VI, Mena MP, et al. Novel monocyclam derivatives as HIV entry inhibitors: Design, synthesis, anti-HIV evaluation, and their interaction with the CXCR4 co-receptor. ChemMedChem 2010;5:1272-81
54. Weiqiang Z, Zhongxing L, Aizhi Z, et al. Discover of small molecule CXCR4 Antagonists. J Med Chem 2007;50:5655-64
55. Zhu A, Zhan W, Liang Z, et al. Dipyridine amines: A novel class of chemokine receptor type 4 antagonists with high specificity. J Med Chem 2010;53:8556-68
56. Bridger GJ, Skerlj RT, Hernandez-Abad PE, et al. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: Analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication. J Med Chem 2010;53:1250-60
57. Skerlj RT, Bridger GJ, Kaller A, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem 2010;53:3376-88
58. De Clercq E. New anti-HIV agents and targets. Med Res Rev 2002;22:531-65 (Pubitemid 35299533)
59. Stone ND, Dunaway SB, Flexner C, et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 2007;51:2351-8 (Pubitemid 47047310)
60. Gudmundsson KS, Sebahar PR, Richardson LD, et al. Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett 2009;19:5048-52
61. Miller JF, Turner EM, Gudmundsson KS, et al. Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents. Bioorg Med Chem Lett 2010;20:2125-8
62. Catalano JG, Gudmundsson KS, Svolto A, et al. Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett 2010;20:2186-90
63. Ueda S, Kato M, Inuki S, et al. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg Med Chem Lett 2008;18:4124-9
64. Tamamura H, Ojida A, Ogawa T, et al. Identification of a new class of low molecular weight antagonists against the chemokine receptor CXCR4 having the dipicolylamine-zinc(II) complex structure. J Med Chem 2006;49:3412-15 (Pubitemid 43830540)
65. Tanaka T, Narumi T, Ozaki T, et al. Azamacrocyclic metal complexes as CXCR4 antagonists. ChemMedChem 2011;6:834-9
66. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 2003;100:4185-90. The development of a non-peptidic CXCR4 antagonist KRH-1636. (Pubitemid 36418178)
67. Iwasaki Y, Akari H, Murakami T, et al. Efficient inhibition of SDF-1alpha-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci 2009;100:778-81
68. Percherancier Y, Berchiche YA, Slight I, et al. Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo-and heterodimers. J Biol Chem 2005;280:9895-903 (Pubitemid 40395837)
69. Berchiche YA, Chow KY, Lagane B, et al. Direct assessment of CXCR4 mutant conformations reveals complex link between receptor structure and G(alpha)(i) activation. J Biol Chem 2007;282:5111-15 (Pubitemid 47093712)
70. Tanaka T, Nomura W, Narumi T, et al. Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells. J Am Chem Soc 2010;132:15899-901
71. Asante-Appiah E, Skalka AM. Molecular mechanisms in retrovirus DNA integration. Antiviral Res 1997;36:139-56 (Pubitemid 28031997)
72. Hindmarsh P, Leis J. Retroviral DNA integration. Microbiol Mol Biol Rev 1999;63:836-43
73. Ellison V, Brown PO. A stable complex between integrase and viral DNA ends mediates human immunodeficiency virus integration in vitro. Proc Natl Acad Sci USA 1994;91:7316-20 (Pubitemid 24226854)
74. Vink C, Lutzke RAP, Plasterk RHA. Formation of a stable complex between the human immunodeficiency virus integrase protein and viral DNA. Nucleic Acids Res 1994;22:4103-10 (Pubitemid 24322711)
75. Wolfe AL, Felock PJ, Hastings JC, et al. The role of manganese in promoting multimerization and assembly of human immunodeficiency virus type 1 integrase as a catalytically active complex on immobilized long terminal repeat substrates. J Virol 1996;70:1424-32 (Pubitemid 26062899)
76. Grobler JA, Stillmock K, Hu B, et al. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA 2002;99:6661-6 (Pubitemid 34526189)
77. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004;305:528-32 (Pubitemid 38971345)
78. Little S, Drusano G, Schooley R, et al. Abstract 161, 12th Conference of Retroviruses and Opportunistic Infections; Boston, MA; 2005
79. Reddy YS, Min SS, Borland J, et al. Safety and pharmacokinetics of GSK364735, a human immunodeficiency virus type 1 integrase inhibitor, following single and repeated administration in healthy adult subjects. Antimicrob Agents Chemother 2007;51:4284-9 (Pubitemid 350209878)
80. Jones GS, Yu F, Zeynalzadegan A, et al. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 2009;53:1194-203
81. Ferrara M, Crescenzi B, Donghi M, et al. Synthesis of a hexahydropyrimido[1,2-a]azepine-2-carboxamide derivative useful as an HIV integrase inhibitor. Tetrahedron Lett 2007;48:8379-82 (Pubitemid 47615082)
82. Sato M, Motomura T, Aramaki H, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006;49:1506-8. The development of an integrase inhibitor Elvitegravir. (Pubitemid 43376497)
83. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43:1-5 (Pubitemid 44306480)
84. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: A novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010;87:322-9
85. Marinello J, Marchand C, Mott BT, et al. Comparison of Raltegravir and Elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008;47:9345-54
86. Bar-Magen T, Sloan RD, Donahue DA, et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010;84:9210-16. The development of an integrase inhibitor MK-2048.
87. Johns BA, Svolto AC. Advances in two-metal chelation inhibitors of HIV integrase. Expert Opin Ther Patents 2008;18:1225-37
88. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ?Antimicrob Agents Chemother 2010;54:254-8. The development of an integrase inhibitor Dolutegravir.
89. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011;55:813-21
90. Ovenden SP, Yu J, Wan SS, et al. Globoidnan A: A lignan from Eucalyptus globoidea inhibits HIV integrase. Phytochemistry 2004;65:3255-9 (Pubitemid 39550393)
91. Valkov E, Gupta SS, Hare S, et al. Functional and structural characterization of the integrase from the prototype foamy virus. Nucleic Acids Res 2009;37:243-55
92. Hare S, Gupta SS, Valkov E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010;464:232-6
93. De Luca L, De Grazia S, Ferro S, et al. HIV-1 integrase strand-transfer inhibitors: Design, synthesis and molecular modeling investigation. Eur J Med Chem 2011;46:756-64
94. Suzuki S, Urano E, Hashimoto C, et al. Peptide HIV-1 integrase inhibitors from HIV-1 gene products. J Med Chem 2010;53:5356-60
95. Suzuki S, Maddali K, Hashimoto C, et al. Peptidic HIV integrase inhibitors derived from HIV gene products: Structure-activity relationship studies. Bioorg Med Chem 2010;18:6771-5
96. Zhao Q, Ma L, Jiang S, et al. Identification of N-phenyl-N'-(2,2,6,6- tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005;339:213-25 (Pubitemid 41169789)
97. Schon A, Madani N, Klein JC, et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 2006;45:10973-80 (Pubitemid 44360167)
98. Yamada Y, Ochiai C, Yoshimura K, et al. CD4 mimics targeting the mechanism of HIV entry. Bioorg Med Chem Lett 2010;20:354-8
99. Narumi T, Ochiai C, Yoshimura K, et al. CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorg Med Chem Lett 2010;20:5853-8
100. Yoshimura K, Harada S, Shibata J, et al. Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol 2010;84:7558-68
101. Lalonde JM, Elban MA, Courter JR, et al. Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Bioorg Med Chem 2011;19:91-101
102. Lu RJ, Tucker JA, Zinevitch T, et al. Design and synthesis of human immunodeficiency virus entryinhibitors: Sulfonamide as an isostere for the alpha-ketoamide group. J Med Chem 2007;50:6535-44 (Pubitemid 350309093)
103. Zou Y-R, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393:595-9 (Pubitemid 28319251)
104. Nakata H, Steinberg SM, Koh Y, et al. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob Agents Chemother 2008;52:2111-19 (Pubitemid 351758548)
105. Abraham M, Biyder K, Begin M, et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist4F-benzoyl- TN14003. Stem Cells 2007; 25:2158-6.
106. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201:1307-18 (Pubitemid 40629073)
107. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-30 (Pubitemid 37248839)
108. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003;47:3123-9 (Pubitemid 37229567)
109. Ghosh AK, Sridhar PR, Leshchenko S, et al. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J Med Chem 2006;49:5252-61 (Pubitemid 44260221)
110. Thayer AM. This is the news from Chemical & Engineering News, American Chemical Society. p29, 2008